pharmaphorum

JUNE 29, 2022

Future booster campaigns against COVID-19 should include vaccines with a component targeting the Omicron variant of SARS-CoV-2, according to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). They are however both based on the original BA.1 1 will be “already somewhat outdated.”

Vaccines 52

Vaccines Immunity Immunization Documentation 52

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added.

Vaccines 52

Vaccines Documentation Immunity Immunization 52

NY Times

OCTOBER 4, 2021

The findings, which also document a waning of protection against infection, come as officials debate the necessity and timing of booster shots.

Hospitals 98

Hospitals Documentation Vaccines Immunity 98

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Communication 81

Communication Vaccines HIPAA Documentation 81

pharmaphorum

FEBRUARY 19, 2021

Two researchers have suggested that the second dose of Pfizer and BioNTech’s COVID-19 vaccine could be delayed, as this would increase the number of people that can be protected while supplies are limited without compromising its efficacy. . Feature image copyright BioNTech SE 2020, all rights reserved.

Vaccines 71

Vaccines Immunity Immunization Documentation 71

pharmaphorum

APRIL 7, 2022

It is too early to consider widespread use of a second COVID-19 vaccine booster dose, according to the European Centre for Disease Prevention and Control (ECDC) and EMA’s COVID-19 task force (ETF). FDA gives first thinking on updating vaccines.

Vaccines 58

Vaccines Immunity Immunization Documentation 58

European Pharmaceutical Review

JUNE 27, 2022

A guidance document has been released to support these activities. GSK now has more than 30 potential new vaccines and medicines in 13 high-burden infectious diseases to accelerate, and we must work collectively with urgency to bring these potentially life-saving innovations to people that need them.”.

Vaccines 88

Vaccines Communication Documentation Compounding 88

Flip the Pharmacy

JUNE 15, 2022

Rightly so, pharmacies have been recognized for their vaccination efforts. The majority of our Certified Pharmacy Technicians willingly and excitingly became certified immunizers. Currently, we’re looking into opportunities for technicians to help document blood pressure and blood glucose measurements.

Pharmacy Technician 52

Pharmacy Technician Packaging Documentation Immunity 52

Flip the Pharmacy

JUNE 21, 2022

Are you interested in expanding vaccine clinics this fall? Perhaps have a "living" technician manual with all of your policy and procedures or training opportunities, like technician immunization training. A document like this can show technicians and other staff how their roles can grow and evolve over time at your pharmacy.

Community Pharmacies 40

Community Pharmacies Medication Delivery Communication Documentation 40

pharmaphorum

JULY 19, 2021

Now, as vaccination continues at pace, the sector has pledged to help “build back better”, by lowering barriers between medical innovations and the patients who need them. In addition, people on ventilators or with weakened immune systems have been at risk of secondary infections, which has further driven up use of antimicrobials.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Vaccines Documentation Immunity 105

pharmaphorum

MARCH 2, 2021

Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.

Vaccines 118

Vaccines Adverse Reactions Documentation Labelling 118

Quality Matters

MAY 24, 2023

World Vaccine Congress 2023: Spotlight shines on mRNA and viral vectored technology platforms Interest in innovative vaccines that use messenger ribonucleic acid (mRNA) and viral vectored technologies was among the key draws at this year’s World Vaccine Congress (WVC) on April 3-6 in Washington, D.C.

Vaccines 52

Vaccines Documentation Immunity Immunization 52

Pharmaceutical Technology

FEBRUARY 1, 2023

Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.

Vaccines 64

Vaccines Documentation Immunity Immunization 64

PharmaShots

JUNE 1, 2023

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients.

Immunity 40

Immunity Immunization Vaccines Health and Personal Care Stores 40

Digital Pharmacist

NOVEMBER 21, 2022

Food and Drug Administration (FDA) announced its approval of the Boostrix vaccine, commonly known as Tdap (combination of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis) for immunization administration during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.

Communication 98

Communication Documentation Pharmacy Management Immunity 98

LifeProNow

APRIL 19, 2023

The primary endpoint evaluated in this study is progression-free survival, defined as time from randomization to the first documentation of progressive disease or death due to any cause, whichever occurs first. The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied.

Adverse Reactions 100

Adverse Reactions Vaccines Immunity Immunization 100

RX Note

FEBRUARY 23, 2023

- Discussing the 4 main drug targets Functional Groups - Quick refresh on IUPAC nomenclature Drug Potency - Refresh on drug potency Drug Metabolism - Discussing Phase I and II reactions, as well as CYP450 system Pharmacogenomics - Discussing some examples Miscellaneous Continuous Professional Development - Needed for renewal of annual retention Immunization (..)

HIV Treatment and Prevention Agents 75

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 75